David A. Siegel Cabaletta Bio, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 471,500 shares of CABA stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
471,500
Previous 831,900
43.32%
Holding current value
$1.03 Million
Previous $1.83 Million
64.21%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CABA
# of Institutions
99Shares Held
37.8MCall Options Held
154KPut Options Held
192K-
Black Rock Inc. New York, NY4.76MShares$10.4 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.97MShares$8.65 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$7.92 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.84MShares$6.2 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.76MShares$6.02 Million1.29% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $63.3M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...